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Abstract
Purpose Quantification of myocardial blood flow (MBF)
with generator-produced 82Rb is an attractive alternative for
centres without an on-site cyclotron. Our aim was to validate
82Rb-measured MBF in relation to that measured using 15O-
water, as a tracer 100% of which can be extracted from the
circulation even at high flow rates, in healthy control subject
and patients with mild coronary artery disease (CAD).
Methods MBF was measured at rest and during adenosine-
induced hyperaemia with 82Rb and 15O-water PET in 33
participants (22 control subjects, aged 30±13 years; 11
CAD patients without transmural infarction, aged 60±
13 years). A one-tissue compartment 82Rb model with ven-
tricular spillover correction was used. The 82Rb flow-
dependent extraction rate was derived from 15O-water meas-
urements in a subset of 11 control subjects. Myocardial flow
reserve (MFR) was defined as the hyperaemic/rest MBF.
Pearson’s correlation r, Bland-Altman 95% limits of agree-
ment (LoA), and Lin’s concordance correlation ρc (measur-
ing both precision and accuracy) were used.
Results Over the entire MBF range (0.66–4.7 ml/min/g),
concordance was excellent for MBF (r00.90, [82Rb–15O-
water] mean difference±SD00.04±0.66 ml/min/g, LoA0
−1.26 to 1.33 ml/min/g, ρc00.88) and MFR (range 1.79–
5.81, r00.83, mean difference00.14±0.58, LoA0−0.99 to
1.28, ρc00.82). Hyperaemic MBF was reduced in CAD
patients compared with the subset of 11 control subjects
(2.53±0.74 vs. 3.62±0.68 ml/min/g, p00.002, for 15O-wa-
ter; 2.53±1.01 vs. 3.82±1.21 ml/min/g, p00.013, for 82Rb)
and this was paralleled by a lower MFR (2.65±0.62 vs. 3.79±
0.98, p00.004, for 15O-water; 2.85±0.91 vs. 3.88±0.91,
p00.012, for 82Rb). Myocardial perfusion was homogeneous
in 1,114 of 1,122 segments (99.3%) and there were no
differences in MBF among the coronary artery territories
(p>0.31).
Conclusion Quantification of MBF with 82Rb with a newly
derived correction for the nonlinear extraction function was
validated against MBF measured using 15O-water in control
subjects and patients with mild CAD, where it was found to
be accurate at high flow rates. 82Rb-derived MBF estimates
seem robust for clinical research, advancing a step further
towards its implementation in clinical routine.
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Introduction
With the advent of hybrid PET/CT driven by oncology
imaging, there are a growing number of centres using
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cardiac PET with 82Rb. This short-lived radioisotope (half-
life 76.4 s) represents an attractive alternative to clinical
imaging, as there is no need for a cyclotron [1–3]. 82Rb
allows clinical imaging with short protocols (20–30 min in
total) and a high patient throughput, providing better image
quality and overall sensitivity in the diagnosis of coronary
artery disease (CAD) as compared to myocardial scintigra-
phy with 201Tl or 99mTc-based radiotracers [2, 4, 5]. It is
currently commercially available in the US, and more re-
cently in Europe [6].
Over the last two decades, investigators have developed
methods for using 82Rb dynamic PET for deriving absolute
quantification of myocardial blood flow (MBF) [7–14].
However, most centres do not take full advantage of the
PET information, as quantification of MBF is not yet imple-
mented in daily clinical routine, although it shows promi-
nent advantages over myocardial scintigraphy [15]. Indeed,
MBF quantification is very relevant to diffusely abnormal
MBF in conditions such as severe or balanced three-vessel
disease and dysfunction of the coronary microcirculation
[16, 17], and even in the absence of angiographic lesions
in primary or secondary cardiomyopathies [18, 19]. There is
growing evidence that important diagnostic or prognostic
information can be gained from quantification of MBF or
MBF reserve (MFR) in addition to myocardial perfusion
imaging [20–26]. The clinical utility of quantification has
gained importance for the diagnosis, prognosis and quanti-
fication of the various disorders of myocardial perfusion [3,
15, 24, 26–28].
Therefore, it is of great importance to be able to quantify
MBF with 82Rb accurately. The quantification of 82Rb MBF
has been compared to 13N-ammonia- or microsphere-
derived MBF in a number of human and animal studies
[14, 29, 30]. MBF quantification might be inaccurate during
maximal hyperaemia, due to the reduced extraction of 82Rb
at high flow rates leading to an important, potentially noisy
correction [15, 28]. It is therefore highly relevant to verify
that quantification of hyperaemic MBF is accurate. Indeed,
it was recently found that the extent of impairment of
maximum hyperaemic MBF is prognostically informative,
as decreased MFR can be due to abnormally increased
resting MBF in the presence of conserved hyperaemic
MBF [31]. Thus, a single measurement of MBF during
vasodilator stress might be sufficient to identify myocardi-
um supplied by an artery with haemodynamically signifi-
cant stenosis and therefore at risk [20, 31].
82Rb-derived MBF quantification has not yet been com-
pared directly with the gold standard for measuring MBF in
humans, 15O-water, a radiotracer 100% of which can be
extracted from the circulation, even at very high flow rates
[32, 33]. Therefore, validation of 82Rb-derived MBF against
MBF measured using 15O-water is an important step, as
quantification using 82Rb is ready to enter daily clinical
practice. Whether MBF quantification with 82Rb is accurate
enough even at high flow rates as compared to quantifica-
tion with 15O-water has not been determined in humans in a
clinical setting with modern PET/CT. To this aim, we
wanted to derive an appropriate 82Rb extraction function
as compared to the 100%-extractible 15O-water and deter-
mine whether a one-tissue compartment model could pro-
vide adequate MBF quantification in a group of healthy
control subjects and patients with mild, stable CAD.
Materials and methods
Study population
Enrolled in the study were 33 subjects (17 men, 16 women)
comprising 22 healthy control subjects (aged 30±13 years)
with no coronary risk factors and a low probability of CAD
(<5%) based on the absence of cardiac symptoms [34], and
11 patients with known, stable CAD (60±13 years) present-
ly free of any cardiac symptoms (typical or atypical chest
pain or angina pectoris equivalent) and without a history of
previous transmural myocardial infarction (this to avoid
biais due to different radiotracer-specific behaviour in
infarcts). Participants underwent a medical history, physical
examination, blood pressure measurements and ECG; fast-
ing blood was collected for routine testing (chemistry and
lipid panel). None of the control subjects was taking any
medication. Pregnancy was excluded in all women of child-
bearing age. The study was performed at two locations
(82Rb in Lausanne and 15O-water in Zurich). Both local
Ethics Committees, as well as the Swiss regulatory author-
ities approved the study protocol. All participants gave
written informed consent before enrolment.
Study protocol
Each participant underwent rest and stress imaging with
82Rb and 15O-water within 4 weeks (median time interval
4 days, interquartile range 2–8 days). They refrained from
taking caffeine-containing substances for at least 24 h and
were asked to fast at least 6 h prior to the PET studies. MBF
was measured at rest and during adenosine-induced phar-
macological vasodilation; the two measurements were sep-
arated by 15 min. Vasodilation was induced with adenosine
(140 μg/kg/min) for 6 min with 82Rb or 15O-water admin-
istration 2.5 min after the start of the infusion. 82RbCl
(1,100 MBq) was obtained from a 82Sr/82Rb generator
(CardioGen-82; Bracco, Princeton, NJ) and injected by an
automated infusion system (RbM Services, LLC, Oakdale,
TN) using a dedicated left-arm venous line (separate from
the line used for adenosine) in 10–20 ml of 0.9% NaCl/water
solution over 10–20 s. 15O-water (700MBq) was produced by
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the University of Zurich Hospital cyclotron and injected
intravenously over 20 s at a rate of 24 ml/min [35]. In all
participants, 12-lead ECG, heart rate and blood pressure were
recorded at 2-min intervals and averaged over the first 2 min
of data acquisition to derive the rate–pressure product (RPP 0
heart rate × systolic blood pressure) as an index of cardiac
work and coronary vascular resistance (CVR 0 mean arterial
blood pressure/MBF).
Image acquisition
Dynamic cardiac PETwas performed with 82Rb in Lausanne
(Discovery LS; GE Medical System, Milwaukee, WI) using
a 10-min acquisition starting immediately after the start of
the 82Rb infusion (21 frames, 35 slices each, 2-D mode,
14.5-cm axial field of view; 12×8, 5×12, 1×30, 1×60, 1×
120 and 1×240 s). Cardiac 15O-water PETwas performed in
Zurich (Discovery ST RX; GE Medical System, Milwaukee,
WI) with the acquisition of a background frame immediately
before the infusion of 15O-water and a 5-min dynamic
acquisition (24 frames, 47 slices each, 2-D mode; 15.2-cm
axial field of view; 14×5, 3×10, 3×20, 4×30 s). First a
scout CT acquisition (120 kV, 10 mA, table speed 10 cm/s)
was performed, followed by a low-dose CT scan for atten-
uation correction (120 kV, 10 mA, 1.0 s per rotation, pitch
0.75) just before the rest 82Rb or 15O-water acquisition. The
low-dose CT scan was repeated immediately after the hyper-
aemic 82Rb acquisition for attenuation correction. The radi-
ation dose for each participant was estimated to be 2×
1.3 mSv for rest and stress 82Rb [36], 2×0.8 mSv for 15O-
water, and 3×0.2 mSv for the low-dose attenuation correc-
tion CT scan [37].
Image processing
Sinograms were corrected for attenuation and reconstructed
on dedicated workstations (GE Medical System, Milwaukee,
WI) using standard iterative reconstruction algorithms
(CHUV comprising OSEM with two iterations and 28 sub-
sets, 3.27-mm FWHM post-filter, 2.34-mm loop filter, and
128×128-pixel matrix size; USZ comprising OSEMwith two
iterations and 28 subsets, 3.49-mm post-filter, 2.50-mm loop
filter, and 128×128-pixel matrix size). Dynamic images were
analysed for 82Rb and 15O-water in a blinded manner
using PMOD 2.85 cardiac PET analysis software
(PMOD Technologies, Zurich, Switzerland). Myocardial
images were generated from the 82Rb and 15O-water
studies and reoriented along short-axis, and vertical
and horizontal long-axis views.
For the 82Rb studies, myocardial images were generated
by averaging the images from 90–600 s. Myocardial vol-
umes of interest (VOI) were drawn on at least 12 consecu-
tive slices. Two VOIs were drawn in the left ventricle (LV)
and right ventricle (RV) on four to six consecutive basal
slices for LV and RV input functions, respectively. For the
15O-water studies, factor images were generated and used
for drawing VOIs. The LV myocardium surface was sub-
divided using the standard 17-segment model of the Amer-
ican Heart Association (AHA). Time–activity curves were
generated for each of the segments and for the blood in the
LVand RVand fitted to a kinetic model to calculate absolute
regional MBF in millilitres per minute per gram. Hyper-
aemic and rest MBF for each segment were divided to
obtain the regional MFR. Global MBF and MFR were
computed from the 17-segment average. Regional values
were derived in each of the coronary artery territories by
averaging the corresponding segments over the left anterior
descending coronary artery (AHA segments 1, 2, 7, 8, 13,
14 and 17), the left circumflex artery (AHA segments 3, 4,
9, 10 and 15) and the right coronary artery (AHA segments
5, 6, 11, 12 and 16) [38].
MBF estimation
A one-tissue compartment model (sometimes called a two-
compartment model) including spillover correction was
employed for fitting the 82Rb time–activity data from the
different myocardial segments [14]. The activity concentration
in the myocardium Cm(t) was calculated asCmðtÞ ¼ K1  ek2t
CLVðtÞ, where K1 and k2 denote the uptake and washout rate
constants of the one-tissue compartment model and CLV(t) the
activity concentration of the blood in the LV, and ⊗ is the
convolution operation. The operational equation which was
fitted to the measurements was given by CPETðtÞ ¼ VLV  CLV
ðtÞ þ VRV  CRVðtÞ þ 1−VLV−VRVð Þ  CmðtÞ , where VLV and
VRV are the fractional contributions of the LV and RV blood
activity to the PET signal measured in the myocardial
segments. K1, k2 and VLV were always fitted, whereas
VRV was only fitted for the septal segments and other-
wise fixed at a value of zero.
To account for the flow-dependent extraction of 82Rb, a
generalized Renkin-Crone function was used to recover MBF
fromK1, as follows:K1 ¼ F  E ¼ F  1−a  e−b=F
 
, where F
is the flow and E is the first-pass flow-dependent extraction
fraction [14, 39]. The a and b factors were determined from
the best fit of the Renkin-Crone function to K1 as a function of
F. F was measured with 15O-water using rest and hyperaemic
MBF from a subset of half of the control subjects (n011), who
were chosen by sampling the 15O-water hyperaemic MBF
values according to quintiles (to obtain uniform sampling
across all hyperaemic MBF values) and by choosing the two
corresponding K1 measurements closest to the median of K1
across the corresponding quintile.
For 15O-water, a standard one-compartment model was
used [35]. For both radioisotopes, the LV and RV time–
activity curves were used to correct for spillover of all LV
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segments and only the septal segments for the RV. Artefacts
due to late starting of the scan relative to the 15O-water
infusion precluded image analysis in two hyperaemic 15O-
water studies.
Statistical analysis
The results are presented as means ± SD. Comparisons
across groups were performed using the t-test or the t-test
after logarithm normalization for skewed data distributions
(only high-sensitivity C-reactive protein in our data). The a
and b parameters for the nonlinear extraction function to
compute 82Rb K1 from
15O-water-derived flow F were de-
rived from a nonlinear least-squares algorithm with 95%
confidence bounds derived from the covariance matrix [40].
The correspondence between the 82Rb and 15O-water
measurement methods was assessed by the Pearson’s corre-
lation coefficient r and the Bland-Altman 95% limit of
agreement methods. In addition, we used the concordance
correlation as proposed by Lin [41], which is essentially
equivalent to the well-known kappa coefficient but is appli-
cable to continuous data. This concordance correlation co-
efficient ρc evaluates both accuracy and precision,
indicating how far the measurement pairs fall from the line
of identity, ranging from +1 (perfect agreement) to 0 (no
agreement) to −1 (perfect inverse agreement) [41–43]. For
graphical representation, we used the reduced major axis
regression line, which is a useful summary of the data and is
defined as the line going through the intersection of the
means with a slope given by the sign of the Pearson’s
correlation r and the ratio of the respective standard devia-
tions. All tests were two-sided and statistical analyses were
performed with Stata 10.1 software (Stata Corporation, Col-
lege Station, TX) using a p value of <0.05 as the signifi-
cance level.
Results
Clinical and laboratory findings
The characteristics of the study groups are listed in Table 1.
CAD patients were older than the control subjects and had
higher mean BMI and systolic blood pressure, although
these mean values were still within the normal ranges. All
patients with hypertension or dyslipidaemia were adequate-
ly treated by medications lowering blood pressure or cho-
lesterol. Mean fasting glucose was normal in CAD patients,
although it was higher than in control subjects. Total, HDL
and LDL cholesterol were similar between the groups, but
the HDL/total cholesterol ratio was higher in CAD patients
than in control subjects. The high-sensitivity CRP was sig-
nificantly higher in CAD patients after logarithm
normalization because of a non-normal, skewed distribu-
tion. All the participating patients had stable CAD without
previous transmural myocardial infarction (three patients
with previously known non-transmural myocardial infarc-
tion) and were presently free of chest pain or angina pectoris
equivalent. All previously documented significant coronary
stenoses (six patients) had been revascularized (by stenting
or coronary artery bypass surgery).
Myocardial perfusion imaging
Visual and semiquantitative analyses of all rest and stress
82Rb myocardial activity images revealed normal uniform
perfusion in the majority of the segments (1,114/1,122 or
99.3%). Myocardial uptake was normal in the 22 control
subjects and 7 patients (summed stress score, SSS00), while
four patients had slightly abnormal myocardial stress polar
maps (all SSS≤2, in one or two segments). One patient with
previous nontransmural myocardial infarction had a fixed
stress and rest defect in two segments corresponding to the
revascularized left circumflex artery (SSS02; summed rest
score, SRS02; summed difference score, SDS00); two
revascularized patients (one with a previously known non-
transmural myocardial infarction in the right coronary ar-
tery) had minor reversible perfusion defects in one segment
(SSS01, SRS00, SDS01), and one unrevascularized pa-
tient had a minor reversible perfusion defect in two seg-
ments (SSS02, SRS00, SDS02). During adenosine
infusion, no ECG ST-segment changes or unexpected side
effects were observed. All daily quality controls of the 82Rb
elution were passed with 82Sr and 85Sr breakthrough values
well below maximal allowed limits (<6% of the allowed
82Sr/82Rb limit of 20×10–6 and <1.7% of the allowed
85Sr/82Rb limit of 200×10–6).
Haemodynamics
The haemodynamic conditions during both 15O-water and
82Rb studies were similar, as indicated by equivalent RPP at
rest (7.6±1.8 vs. 7.4±1.7×103·min-1·mmHg, respectively;
p00.28) and during hyperaemia (10.0±2.1 vs. 9.9±2.0×
103·min-1·mmHg, respectively; p00.48). One control sub-
ject declined repeated adenosine administration due to un-
pleasant symptoms experienced during his first study
(flush), which were however within the range of commonly
observed side effects of adenosine.
Extraction function of 82Rb
The generalized Renkin-Crone function was fitted to the
82Rb K1 values as a function of the
15O-water MBF in half
of the control subjects (n011) to derive the a and b con-
stants. The fit was excellent (a00.80, b00.59 ml/min/g,
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R200.97, RMSE00.165) allowing conversion of the K1 rate
constant estimates to MBF (Fig. 1).
MBF findings
A scatter plot showing the concordance between the 82Rb
and 15O-water MBF is shown in Fig. 2a. Over the whole
MBF range (0.66–4.7 ml/min/g), the reduced major axis
was close to the line of perfect concordance. Pearson’s
correlation r was 0.89, and Lin’s concordance correlation
ρc was 0.88 (95% CI 0.82–0.94). A Bland-Altman plot
(Fig. 2b) showed good agreement (95% limits of
agreement0±1.96×SD01.30, or −1.26 to 1.34 ml/min/g)
and no mean difference (0.04±0.66 ml/min/g, or 2±33%,
p00.69) in the MBF measurements. When performed
separately, the mean and 95% limits of agreement for rest
MBF and stress MBF were −0.02 ml/min/g (±1.96×SD0
0.46, or −0.048 to 0.044 ml/min/g) and −0.10 ml/min/g
(±1.96 × SD 01.79, or −1.69 to 0.1.89 ml/min/g),
respectively.
Table 1 Characteristics of the
33 study participants
HOMA-IR homeostasis model
assessment of insulin resistance.
Variable Controls (n022) CAD patients (n011) P
Age (years) 30±13 60±13 <0.001
Body mass index (kg/m2) 22.5±2.3 26.7±3.4 0.001
Blood pressure (mmHg) 111±11/63±10 129±19/66±11 0.004/0.40
Fasting plasma glucose (mmol/l) 4.12±0.75 5.11±0.65 0.002
Total cholesterol (mmol/l) 4.55±0.66 4.77±1.00 0.48
HDL cholesterol (mmol/l) 1.65±0.46 1.37±0.34 0.059
LDL cholesterol (mmol/l) 2.74±1.01 2.52±0.55 0.44
HDL/total cholesterol index 2.88±0.67 3.74±1.55 0.043
Triglyceride level (mmol/l) 0.86±0.32 1.42±0.58 0.002
High-sensitivity CRP (mg/l) 2.2±2.3 13±26 0.009
HOMA-IR 1.9±0.7 2.7±0.6 0.042
Hypertension 0 (0%) 5 (45%) 0.002
Dyslipidaemia 0 (0%) 7 (64%) <0.001
Obesity 0 (0%) 2 (18%) 0.10
Diabetes 0 (0%) 1 ( 9%) 0.33
Smoking 0 (0%) 2 (18%) 0.10
Familial history of early CAD 0 (0%) 1 ( 9%) 0.33
Previous revascularization 0 (0%) 6 (55%) <0.001
Left anterior descending artery – 5 (45%) –
Left circumflex artery – 3 (27%) –
Right coronary artery – 2 (18%) –
Previous nontransmural infarction 0 (0%) 3 (27%) 0.030
Left anterior descending artery – 1 (9%) –
Left circumflex artery – 1 (9%) –
Right coronary artery – 1 (9%) –
Typical or atypical angina 0 (0%) 0 (0%) 1.0
Shortness of breath 0 (0%) 0 (0%) 1.0
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Fig. 1 Scatter plot of 82Rb K1 rate constant vs.
15O-water MBF
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A scatter plot for MFR also showed good concordance
over the whole MFR range (1.79–5.81) with a reduced major
axis almost equal to the line of identity (Fig. 3a). The
corresponding Pearson’s correlation r was 0.83 and Lin’s
concordance correlation ρc was 0.82 (95% CI 0.68–0.96). A
Bland-Altman plot (Fig. 3b) also showed excellent concor-
dance (95% limits of agreement0±1.96×SD01.14, or −0.99
to 1.28) and no significant mean difference (0.14±0.58, or 4±
18%, p00.26).
Values of MBF at rest and during stress, MFR and CVR
in the CAD patients and control subjects are shown in
Table 2 for both 82Rb and 15O-water cardiac PET., there
was no significant MBF group difference at rest, while
both hyperaemic MBF and MFR were significantly de-
creased in CAD patients as compared to control subjects,
with a corresponding higher hyperaemic CVR in CAD
patients.
Discussion
Quantification of MBF with 82Rb cardiac PET is of increasing
clinical and prognostic value, but its accuracy against quanti-
fication using 15O-water, a tracer 100% of which can be
extracted from the circulation, has not been validated at very
high MBF rates such as during hyperaemia. The extraction
function of 82Rb was derived in normal control subjects from
comparison with 15O-water allowed the K1 parameter to be
accurately converted with an excellent fit to blood flow, even
at high flow rates. Using this function in a second, different
group of control subjects and CAD patients, excellent concor-
dance and agreement was obtained between MBF or MFR
derived from 15O-water and 82Rb without a systematic mean
difference over the whole range of rest and hyperaemic flows.
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Fig. 2 a Scatter plot shows concordance between MBF measurements
by 82Rb and 15O-water in the second group of 11 control subjects and
in a group of 11 CAD patients with a reduced major axis close to the
line of identity. b Corresponding Bland-Altman plot
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Finally, in our group of patients with mild CAD with homo-
geneous myocardial perfusion in the majority of segments,
MBF quantification with either 82Rb or 15O-water revealed
significantly decreased MBF, MFR and CVR as compared to
control subjects.
The a and b parameters found in our study (a00.80, b0
0.59 ml/min/g) are close to the parameters obtained by Lortie
et al. using a similar process with 13N-ammonia cardiac PET
in 14 healthy subjects (a00.77, b00.63 ml/min/g) and the
factors determined by Schelbert [39] based on a study by
Glatting et al. [44] using the argon inert gas method (a0
0.73, b00.59 ml/min/g). These a and b parameters are known
to represent the flow-dependent permeability surface product,
PS (PS0 ln(1/a)×F+b, i.e. 0.22×F+0.59 in our study) due to
increased capillary recruitment that is related to the extraction
fraction (E01−e−PS/F) [8, 45]. The differences among these
three extraction curves can be appreciated in Fig. 4, showing
that parameters derived in this study lead to slightly larger
corrections at higher flows than both other methods. To verify
the validity of our 82Rb extraction function derivation from
15O-water, we performed the same fit using the other half of
the control subjects (n011) and obtained almost identical fit
parameters (a00.80, b00.58 ml/min/g, R200.96, RMSE0
0.186). This shows robustness of the proposed sampling ap-
proach across quintiles of 15O-water hyperaemic flows to get
unbiased estimates of the 82Rb extraction function.
Comparisons were made with the Lin’s concordance corre-
lation coefficient, as it is the most appropriate test for assessing
the equivalence of two methods of measurements [41–43]. It
offers more insight into the observed differences, as ρc equals
the product of the standard Pearson’s correlation r (a measure
of imprecision) and the bias coefficient cb (a measure of
inaccuracy). Among well-known approaches to compare data
from two measurement methods, Lin’s concordance correla-
tion offers many advantages. Indeed, when comparing data
obtained with two measurement methods, the Pearson’s corre-
lation coefficient alone fails to detect a departure from the 45°
line through the origin, thus ignoring inaccuracy. Using the
conventional paired t-test between corresponding data from
each method could lead to rejecting a well reproducible
method due to a very small residual error. With the least
squares approach, one would fail to detect departure from
slope01 and intercept00 if the data were very scattered. Fi-
nally, the coefficient of variation and the intraclass coefficient
of correlation would not distinguish bias from imprecision.
In our study, most MBF and MFR differences were due
to imprecision (intrasample variations), as the bias correc-
tion factors were very close to 1 (cb0ρc/r00.99 for both
MBF and MFR), indicating an excellent accuracy between
82Rb and 15O-water. The Lin’s concordance correlation was
slightly higher for MBF than for MFR, but the difference
was not statistically significant, as shown by overlapping
confidence intervals. The use of correlations is only mean-
ingful when comparisons are performed over the whole
clinical range of potential MBF or MFR, since agreement
over a small range cannot be extrapolated to a wider range.
This is the reason why rest and stress measurements for both
patients and control subjects were considered together for
this analysis. However, similar findings were found when
Table 2 MBF at rest and during
stress, MFR and CVR in both
control subjects and CAD
patients
Cardiac PET tracer Variable Control subjects
(n=11)
CAD patients
(n=11)
p value
15O-water Rest MBF (ml/min/g) 1.00±0.24 0.95±0.16 0.64
Stress MBF (ml/min/g) 3.62±0.68 2.53±0.74 0.002
MFR 3.79±0.98 2.65±0.62 0.004
Stress CVR (mmHg/ml·min·g) 23±6 37±13 0.005
82Rb Rest MBF (ml/min/g) 1.03±0.42 0.88±0.21 0.33
Stress MBF (ml/min/g) 3.82±1.21 2.53±1.01 0.013
MFR 3.88±0.91 2.85±0.86 0.012
Stress CVR (mmHg/ml·min·g) 23±9 38±17 0.017
0.0
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0.4
0.6
0.8
1.0
82
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E=1−0.73*exp(−0.59/F), Glatting et al. 1995
E=1−0.77*exp(−0.63/F), Lortie et al. 2007
E=1−0.80*exp(−0.59/F), Prior et al. 2012
Fig. 4 Plot of the function relating extraction (E) for 82Rb to flow
estimates (F) derived from the present study in control subjects using
15O-water in comparison to previous studies using 13N-ammonia
PET (Lortie et al. [14]) or the argon inert gas method (computed by
Schelbert [39] based on a study by Glatting et al. [44])
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control subjects and patients were analysed separately, with
ρc for MBF of 0.86 in control subjects and 0.90 in patients,
respectively. The corresponding values for MFR were of
0.87 in control subjects and 0.56 in patients), respectively.
Interestingly, this last value for MFR in patients was slightly
but not significantly lower than that in control subjects, due
to a significantly lower range of MFR in patients than in
control subjects. Although this was not the purpose of our
study, good concordances were found in each coronary
artery territory, and no significant differences in regional
MBF were observed among coronary artery territories re-
garding concordance of 82Rb vs. 15O-water measurements
(ρc00.89, 95% CI 0.83–0.95, for the left anterior descend-
ing artery: ρc00.80, 95% CI 0.69–0.90, for the left circum-
flex artery; ρc00.77, 95% CI 0.66–0.88, for the right
coronary artery), although the left anterior descending and
left circumflex territories values were slightly but not sig-
nificantly better than the right coronary territory values.
Finally, we wondered if 82Rb measurements across coronary
territories were subject to wider variations than 15O-water
measurements, but using the variance ratio test no differ-
ences in the standard deviations of the measurements were
observed (SD01.43 for all 82Rb measurements, SD01.20
for all 15O-water measurements, p00.17).
The Bland-Altman limit of agreement method showed a
good to excellent agreement for MBF and MFR, with only a
few measurement pairs outside the limits of agreement,
confirming a normal distribution of the measurements.
There was a variability of pharmacologically induced hyper-
aemia, as previously reported, with differences up to 12±
12% in stress MBF [46, 47]. Thus, the observed differences
between the 82Rb and 15O-water studies (−2±33%) may be
attributable largely to physiological variability as opposed to
methodological biases due to differences in location, time or
sequence order of the 82Rb and 15O-water measurements. It
is worth noting that we found similar limits of agreements
for rest MBF (−0.02±0.46, mean±1.96×SD) to those found
by Yoshinaga et al. (−0.05±0.49, mean±1.96×SD) [16].
The MBF and MFR means and ranges obtained with 82Rb
in healthy control subjects and patients with CAD are compa-
rable to previously published values in these groups [14, 48,
49]. Interestingly, the group difference was even more signif-
icant when considering the CVR that takes into account the
effect of arterial pressure. Decreases in MBF and MFR in
CAD patients in relation to control subjects were seen with
82Rb as well as with the gold standard 15O-water. Thus, it
should be possible to perform clinical studies comparingMBF
or MFR among groups using 82Rb-based quantitation.
The quantitative aspect of cardiac PET may actually
reveal more extensive disease than myocardial scintigraphy
or nonquantitative PET [5, 50], which frequently shows
decreased perfusion only in the myocardial area supplied
by the artery with the most severe stenosis [51]. In keeping
with these results, Sampson at al. have recently found that
45% of patients with multivessel CAD on coronary angiog-
raphy had stress perfusion defects in only one territory on
nonquantitative visual analysis of 82Rb cardiac PET/CT and
21% of the patients with one-vessel CAD on coronary
angiography had stress PET abnormalities in more than
one territory [5].
In our study, the myocardium was affected similarly in
most territories in most of the CAD patients, with only four
patients with regionally decreased MBF and MFR of very
limited extent (one or two segments). Moreover, only a few
patients showed mildly reduced MFR (<2.0–2.5), in agree-
ment with the absence of previous transmural myocardial
infarction and the presence of only mild diffuse coronary
artery stenosis or effective previous revascularization. This
suggests that patients with multiple coronary risk factors
have a uniformly decreased response to pharmacological
vasodilation due to diffuse (micro- or macrovascular) endo-
thelial dysfunction without necessarily having obstructive
CAD [16, 17], which may be underestimated when measur-
ing stenosis severity alone, as previously shown [52, 53].
Importantly, nonquantitative 82Rb cardiac PET assessment
has been shown to be valuable for risk stratification of future
cardiovascular events, even after nondiagnostic myocardial
SPECT scintigraphy [38]. Recently the additional prognos-
tic power has been shown to be enhanced by quantitative
MFR measurements [21, 24–26]. Whether this can be fur-
ther enhanced by absolute measurement of hyperaemic
MBF alone remains to be determined [54].
Cardiac PET and PET/CT myocardial perfusion im-
aging is becoming a clinically mature, cost-effective
method [2, 4–6, 35, 52]. Further benefits over conven-
tional myocardial SPECT scintigraphy include higher
specificity, sensitivity and accuracy [4], lower patient
and technologist/physician radiation doses [55], shorter
examination duration, and the capacity to quantitate
MBF and MFR. It was recently demonstrated to be
cost-effective in the clinical setting [56]. Generator-
produced 82Rb certainly has several key advantages over
other PET radiopharmaceuticals such as 15O-water or
13N-ammonia: its use obviates the need for a cyclotron
and, compared to the use of 13N-ammonia, allows a
higher patient throughput [57]. Notably, all 82Rb cardiac
PET examinations performed in our study led to suc-
cessful MBF quantitation, further indicating its clinical
feasibility. However, special attention to technical details
is necessary, especially to possible misregistration arte-
facts, which may present as shifts between attenuation
correction and the PET images [58]. MBF quantitation
processing, challenging in the past, is becoming easier
and faster with the advent of software dedicated to
cardiac processing with automated reorientation and
myocardial VOI drawing [59, 60].
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This study had a few limitations which should be men-
tioned. The fact that MBF was not measured during the same
session so that differences in time, location and possibly
hyperaemic flow may have increased the observed random
intrasample variations leading to an underestimation of true
concordance. We excluded patients with previous myocardial
infarction so as not to introduce additional MBF bias from
known differences in radiotracer behaviour in myocardial scar
due to tissue fibrosis [61, 62]. The abnormal myocardial
perfusion seen in four CAD patients may have affected our
comparisons based on MBF averaged over the 17 LV seg-
ments, although the defects were moderate in severity, limited
in extent, and affected similar segments on the 82Rb and 15O-
water studies; furthermore, no significant differences were
observed among coronary artery territories or when these four
patients were excluded from the analysis. Great care was taken
in the execution of the PET/CT studies to avoid any misreg-
istration between the attenuation-correction CT image and the
PET image, notably by repeating the attenuation-correction
CT scan immediately after the pharmacological stress. Al-
though alignment between PET and CT images was excellent
with no displacement greater than 5 mm, it is nevertheless
possible that smaller image shifts may still have influenced
MBF quantification, resulting in a slight degradation of con-
cordance and agreement.
Quantification of MBF with 82Rb with a newly derived
correction for the nonlinear extraction function was validated
against 15O-water in control subjects and patients with mild
CAD. It was found to be accurate event at high flow rates
using modern PET/CT and commercially available software.
Thus, 82Rb-derived MBF estimates are robust in the clinical
setting even at higher flow rates, advancing a step further
towards its routine implementation in clinical practice.
Acknowledgments The authors are indebted to Mr. Jérôme Malterre
and Luca Modolo (in Lausanne), Mr. Ratko Milovanovic and Dr.
Tobias Hoefflinghaus (in Zurich) for assisting in the studies, and to
Rolf R. Hesselmann, PhD (Cyclotron Unit, Zurich) for 15O-water
radioisotope production. They also would like to thank Drs. Kathrin
Marx, MD, for logistic support and David W. Crook, MD, for editorial
assistance.
This work was supported by research grants from the Swiss Nation-
al Science Foundation (grant no. 320000-109986), the Michel Tossizza
Foundation (Lausanne, Switzerland), and the Société Académique
Vaudoise (Lausanne, Switzerland). P.A.K. was supported by the Swiss
National Science Foundation (grant no. PP00A-114706). J.O.P. was a
recipient of an Academic Research Award from the Leenaards Foun-
dation (Lausanne, Switzerland).
Conflicts of interest None.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
References
1. Gould KL, Goldstein RA, Mullani NA, Kirkeeide RL, Wong WH,
Tewson TJ, et al. Noninvasive assessment of coronary stenoses by
myocardial perfusion imaging during pharmacologic coronary va-
sodilation. VIII. Clinical feasibility of positron cardiac imaging
without a cyclotron using generator-produced rubidium-82. J Am
Coll Cardiol. 1986;7:775–89.
2. Machac J. Cardiac positron emission tomography imaging. Semin
Nucl Med. 2005;35:17–36.
3. Schelbert HR. Quantification of myocardial blood flow: what is
the clinical role? Cardiol Clin. 2009;27:277–89.
4. Bateman TM, Heller GV, McGhie AI, Friedman JD, Case JA,
Bryngelson JR, et al. Diagnostic accuracy of rest/stress ECG-
gated Rb-82 myocardial perfusion PET: comparison with
ECG-gated Tc-99m sestamibi SPECT. J Nucl Cardiol.
2006;13:24–33.
5. Sampson UK, Dorbala S, Limaye A, Kwong R, Di Carli MF.
Diagnostic accuracy of rubidium-82 myocardial perfusion imaging
with hybrid positron emission tomography/computed tomography
in the detection of coronary artery disease. J Am Coll Cardiol.
2007;49:1052–8.
6. Groves AM, Speechly-Dick ME, Dickson JC, Kayani I, Endozo R,
Blanchard P, et al. Cardiac (82)rubidium PET/CT: initial European
experience. Eur J Nucl Med Mol Imaging. 2007;34:1965–72.
7. Herrero P, Markham J, Shelton ME, Weinheimer CJ, Bergmann
SR. Noninvasive quantification of regional myocardial perfusion
with rubidium-82 and positron emission tomography. Exploration
of a mathematical model. Circulation. 1990;82:1377–86.
8. Yoshida K, Mullani N, Gould KL. Coronary flow and flow reserve
by PET simplified for clinical applications using rubidium-82 or
nitrogen-13-ammonia. J Nucl Med. 1996;37:1701–12.
9. Huang SC, Williams BA, Krivokapich J, Araujo L, Phelps ME,
Schelbert HR. Rabbit myocardial 82Rb kinetics and a compart-
mental model for blood flow estimation. Am J Physiol. 1989;256:
H1156–64.
10. Herrero P, Markham J, Shelton ME, Bergmann SR. Implementa-
tion and evaluation of a two-compartment model for quantification
of myocardial perfusion with rubidium-82 and positron emission
tomography. Circ Res. 1992;70:496–507.
11. Coxson PG, Huesman RH, Borland L. Consequences of using a
simplified kinetic model for dynamic PET data. J Nucl Med.
1997;38:660–7.
12. Lin JW, Sciacca RR, Chou RL, Laine AF, Bergmann SR. Quanti-
fication of myocardial perfusion in human subjects using 82Rb and
wavelet-based noise reduction. J Nucl Med. 2001;42:201–8.
13. El Fakhri G, Sitek A, Guerin B, Kijewski MF, Di Carli MF, Moore
SC. Quantitative dynamic cardiac 82Rb PET using generalized
factor and compartment analyses. J Nucl Med. 2005;46:1264–71.
14. Lortie M, Beanlands RS, Yoshinaga K, Klein R, Dasilva JN,
Dekemp RA. Quantification of myocardial blood flow with (82)
Rb dynamic PET imaging. Eur J Nucl Med Mol Imaging.
2007;34:1765–74.
15. Knuuti J, Kajander S, Maki M, Ukkonen H. Quantification of
myocardial blood flow will reform the detection of CAD. J Nucl
Cardiol. 2009;16:497–506.
16. Yoshinaga K, Manabe O, Katoh C, Chen L, Klein R, Naya M, et al.
Quantitative analysis of coronary endothelial function with
generator-produced 82Rb PET: comparison with 15O-labelled wa-
ter PET. Eur J Nucl Med Mol Imaging. 2010;37:2233–41.
17. Yoshinaga K, Manabe O, Tamaki N. Assessment of coronary
endothelial function using PET. J Nucl Cardiol. 2011;18:486–500.
18. Beanlands RS, Muzik O, Melon P, Sutor R, Sawada S, Muller D, et
al. Noninvasive quantification of regional myocardial flow reserve
in patients with coronary atherosclerosis using nitrogen-13
Eur J Nucl Med Mol Imaging (2012) 39:1037–1047 1045
ammonia positron emission tomography. Determination of extent
of altered vascular reactivity. J Am Coll Cardiol. 1995;26:1465–
75.
19. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J
Med. 2007;356:830–40.
20. Hajjiri MM, Leavitt MB, Zheng H, Spooner AE, Fischman AJ,
Gewirtz H. Comparison of positron emission tomography mea-
surement of adenosine-stimulated absolute myocardial blood flow
versus relative myocardial tracer content for physiological assess-
ment of coronary artery stenosis severity and location. JACC
Cardiovasc Imaging. 2009;2:751–8.
21. Herzog BA, Husmann L, Valenta I, Gaemperli O, Siegrist PT,
Tay FM, et al. Long-term prognostic value of 13N-ammonia
myocardial perfusion positron emission tomography added
value of coronary flow reserve. J Am Coll Cardiol.
2009;54:150–6.
22. Knaapen P, Camici PG, Marques KM, Nijveldt R, Bax JJ,
Westerhof N, et al. Coronary microvascular resistance: meth-
ods for its quantification in humans. Basic Res Cardiol.
2009;104:485–98.
23. Neglia D, L'Abbate A. Myocardial perfusion reserve in ischemic
heart disease. J Nucl Med. 2009;50:175–7.
24. Tio RA, Dabeshlim A, Siebelink HM, de Sutter J, Hillege
HL, Zeebregts CJ, et al. Comparison between the prognostic
value of left ventricular function and myocardial perfusion
reserve in patients with ischemic heart disease. J Nucl Med.
2009;50:214–9.
25. Fukushima K, Javadi MS, Higuchi T, Lautamaki R, Merrill J,
Nekolla SG, et al. Prediction of short-term cardiovascular events
using quantification of global myocardial flow reserve in patients
referred for clinical 82Rb PET perfusion imaging. J Nucl Med.
2011;52:726–32.
26. Ziadi MC, Dekemp RA, Williams KA, Guo A, Chow BJ, Renaud
JM, et al. Impaired myocardial flow reserve on rubidium-82 pos-
itron emission tomography imaging predicts adverse outcomes in
patients assessed for myocardial ischemia. J Am Coll Cardiol.
2011;58:740–8.
27. Beanlands RS, Ziadi MC, Williams K. Quantification of myocar-
dial flow reserve using positron emission imaging the journey to
clinical use. J Am Coll Cardiol. 2009;54:157–9.
28. Camici PG, Rimoldi OE. The clinical value of myocardial blood
flow measurement. J Nucl Med. 2009;50:1076–87.
29. Lautamaki R, George RT, Kitagawa K, Higuchi T, Merrill J,
Voicu C, et al. Rubidium-82 PET-CT for quantitative assess-
ment of myocardial blood flow: validation in a canine model
of coronary artery stenosis. Eur J Nucl Med Mol Imaging.
2009;36:576–86.
30. El Fakhri G, Kardan A, Sitek A, Dorbala S, Abi-Hatem N, Lahoud
Y, et al. Reproducibility and accuracy of quantitative myocardial
blood flow assessment with 82Rb PET: comparison with 13N-
ammonia PET. J Nucl Med. 2009;50:1062–71.
31. Camici PG. Absolute figures are better than percentages. JACC
Cardiovasc Imaging. 2009;2:759–60.
32. Bergmann SR, Fox KA, Rand AL, McElvany KD, Welch MJ,
Markham J, et al. Quantification of regional myocardial blood
flow in vivo with H215O. Circulation. 1984;70:724–33.
33. Bol A, Melin JA, Vanoverschelde JL, Baudhuin T, Vogelaers
D, De Pauw M, et al. Direct comparison of [13N]ammonia
and [15O]water estimates of perfusion with quantification of
regional myocardial blood flow by microspheres. Circulation.
1993;87:512–25.
34. Diamond GA, Forrester JS. Analysis of probability as an aid in the
clinical diagnosis of coronary artery disease. N Engl J Med.
1979;300:1350–8.
35. Adachi I, Gaemperli O, Valenta I, Schepis T, Siegrist PT, Treyer V,
et al. Assessment of myocardial perfusion by dynamic O-15-
labeled water PET imaging: validation of a new fast factor analy-
sis. J Nucl Cardiol. 2007;14:698–705.
36. Senthamizhchelvan S, Bravo PE, Esaias C, Lodge MA, Merrill J,
Hobbs RF, et al. Human biodistribution and radiation dosimetry of
82Rb. J Nucl Med. 2010;51:1592–9.
37. Einstein AJ, Moser KW, Thompson RC, Cerqueira MD, Henzlova
MJ. Radiation dose to patients from cardiac diagnostic imaging.
Circulation. 2007;116:1290–305.
38. Yoshinaga K, Chow BJ, Williams K, Chen L, de Kemp RA,
Garrard L, et al. What is the prognostic value of myocardial
perfusion imaging using rubidium-82 positron emission tomogra-
phy? J Am Coll Cardiol. 2006;48:1029–39.
39. Schelbert HR. Positron emission tomography of the heart: method-
ology, findings in the normal and the diseased heart, and clinical
applications. In: Phelps ME, editor. Molecular imaging and its bio-
logical applications. 1st ed. New York: Springer; 2004. p. 389–508.
40. Royston P. sg1.2: nonlinear regression command. Stata Tech Bull.
1992;7:11–8.
41. Lin LI. A concordance correlation coefficient to evaluate repro-
ducibility. Biometrics. 1989;45:255–68.
42. Lin LIK. Assay validation using the concordance correlation coef-
ficient. Biometrics. 1992;48:599–604.
43. Correction: A Note on the Concordance Correlation Coefficient.
Biometrics 2000;56:324–5.
44. Glatting G, Bergmann KP, Stollfuß JC, Weismüller P, Kochs M,
Hombach V, et al. Myocardial Rb Extraction Fraction: Determina-
tion in Humans. Journal of the American College of Cardiology
1995;25:364A–5A.
45. Schelbert HR, Phelps ME, Huang SC, MacDonald NS, Hansen H,
Selin C, et al. N-13 ammonia as an indicator of myocardial blood
flow. Circulation. 1981;63:1259–72.
46. Kaufmann PA, Gnecchi-Ruscone T, Yap JT, Rimoldi O, Camici
PG. Assessment of the reproducibility of baseline and hyperemic
myocardial blood flow measurements with 15O-labeled water and
PET. J Nucl Med. 1999;40:1848–56.
47. Nagamachi S, Czernin J, Kim AS, Sun KT, Bottcher M, Phelps
ME, et al. Reproducibility of measurements of regional resting and
hyperemic myocardial blood flow assessed with PET. J Nucl Med.
1996;37:1626–31.
48. Manabe O, Yoshinaga K, Katoh C, Naya M, De Kemp RA, Tamaki
N. Repeatability of rest and hyperemic myocardial blood flow meas-
urements with 82Rb dynamic PET. J Nucl Med. 2009;50:68–71.
49. Sdringola S, Johnson NP, Kirkeeide RL, Cid E, Gould KL. Impact
of unexpected factors on quantitative myocardial perfusion and
coronary flow reserve in young, asymptomatic volunteers. JACC
Cardiovasc Imaging. 2011;4:402–12.
50. Yoshinaga K, Katoh C, Noriyasu K, Iwado Y, Furuyama H, Ito Y,
et al. Reduction of coronary flow reserve in areas with and without
ischemia on stress perfusion imaging in patients with coronary
artery disease: a study using oxygen 15-labeled water PET. J Nucl
Cardiol. 2003;10:275–83.
51. Uren NG, Crake T, Lefroy DC, de Silva R, Davies GJ, Maseri A.
Reduced coronary vasodilator function in infarcted and normal myo-
cardium after myocardial infarction. N Engl J Med. 1994;331:222–7.
52. Gould KL. Positron emission tomography in coronary artery dis-
ease. Curr Opin Cardiol. 2007;22:422–8.
53. Sdringola S, Loghin C, Boccalandro F, Gould KL. Mechanisms of
progression and regression of coronary artery disease by PET
related to treatment intensity and clinical events at long-term
follow-up. J Nucl Med. 2006;47:59–67.
54. Bengel FM. Leaving relativity behind: quantitative clinical perfu-
sion imaging. J Am Coll Cardiol. 2011;58:749–51.
55. Schleipman AR, Castronovo Jr FP, Di Carli MF, Dorbala S. Oc-
cupational radiation dose associated with Rb-82 myocardial perfu-
sion positron emission tomography imaging. J Nucl Cardiol.
2006;13:378–84.
1046 Eur J Nucl Med Mol Imaging (2012) 39:1037–1047
56. Siegrist PT, Husmann L, Knabenhans M, Gaemperli O, Valenta I,
Hoefflinghaus T, et al. (13)N-ammonia myocardial perfusion imag-
ing with a PET/CT scanner: impact on clinical decision making and
cost-effectiveness. Eur J Nucl Med Mol Imaging. 2008;35:889–95.
57. Kaufmann PA. 82-Rubidium – the dawn of cardiac PET in Europe?
Eur J Nucl Med Mol Imaging. 2007;34:1963–4.
58. Gould KL, Pan T, Loghin C, Johnson NP, Guha A, Sdringola S.
Frequent diagnostic errors in cardiac PET/CT due to misregistration
of CT attenuation and emission PET images: a definitive analysis of
causes, consequences, and corrections. J Nucl Med. 2007;48:1112–21.
59. PMOD Technologies. User's guide: PMOD Cardiac Modeling
(PCARD). http://www.pmod.ch/technologies/pdf/doc/PCARD.
pdf. Accessed 10 Feb 2012.
60. Klein R, Renaud JM, Ziadi MC, Thorn SL, Adler A, Beanlands RS, et
al. Intra- and inter-operator repeatability of myocardial blood flow and
myocardial flow reserve measurements using rubidium-82 pet and a
highly automated analysis program. J Nucl Cardiol. 2010;17:600–16.
61. Nitzsche EU, Choi Y, Czernin J, Hoh CK, Huang SC, Schelbert
HR. Noninvasive quantification of myocardial blood flow in
humans. A direct comparison of the [13N]ammonia and the
[15O]water techniques. Circulation. 1996;93:2000–6.
62. Gerber BL, Wijns W, Vanoverschelde JL, Heyndrickx GR, De
Bruyne B, Bartunek J, et al. Myocardial perfusion and oxygen
consumption in reperfused noninfarcted dysfunctional myocardi-
um after unstable angina: direct evidence for myocardial stunning
in humans. J Am Coll Cardiol. 1999;34:1939–46.
Eur J Nucl Med Mol Imaging (2012) 39:1037–1047 1047
